Business Wire | Jan 5, 2022 08:30AM EST

Bone Biologics to Present at the H.C. Wainwright BioConnect Virtual Conference

Jan. 05, 2022

BURLINGTON, Mass.--(BUSINESS WIRE)--Jan. 05, 2022--Bone Biologics Corporation(NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced that Jeffrey Frelick, the Company's president and chief executive officer, will present at the H.C. Wainwright BioConnect Virtual Conference being held January 10 - 13, 2022. A pre-recorded presentation will be available beginning Monday, January 10 at 7:00 a.m. Eastern time. Interested parties may access a webcast of the presentation on the investor relations section of the Company's website and at this link.

About Bone BiologicsBone Biologics was founded to pursue regenerative medicine for bone. The Company is undertaking groundbreaking work with select strategic partners, building on unprecedented research on the Nell-1 protein that has produced a significant number of studies and publications in peer reviewed scientific literature. Bone Biologics is currently focusing its development efforts for its bone graft substitute product on bone regeneration in spinal fusion and has rights to trauma and osteoporosis applications. For more information, please visit www.bonebiologics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005202/en/

CONTACT: LHA Investor Relations Kim Sutton Golodetz 212-838-3777 kgolodetz@lhai.com